Modifications in relaxin’s serum levels during acetatefree biofiltration (AFB): only a new biomarker?

Valeria Cernaro, Antonio Lacquaniti, Grazia Giorgianni, Davide Bolignano, Michele Buemi

Abstract


Aims.We evaluated relaxin’s behaviour during a haemodialytic session and the effects of its intradialytic variability on blood pressure. Methods. We enrolled 25 patients and evaluated relaxin’s levels during a haemodialytic session. We also dosed interdialytic relaxin and enrolled 10 healthy subjects and 16 patients with III stage chronic renal failure as controls. Results. Haemodialyzed patients have relaxin’s baseline concentrations higher than healthy controls, but lower than chronic patients. During the treatment, relaxin is removed; it increases again throughout the interdialytic phase. Furthermore, relaxin’s pre- haemodialytic concentration positively and significantly correlates with systolic, diastolic, and mean BP; such correlations disappear at the end of the treatment. Conclusion. Relaxin’s removal during the treatment may intervene in the pathogenesis of intradialytic hypertension. Hence, relaxin could be not only a new biomarker but also an active player in the intradialytic variations of blood pressure.


Keywords


acetate-free haemodialysis; blood pressure; pleiotropic hormone; relaxin; intradialytic hypertension

Full Text:

PDF


DOI: http://dx.doi.org/10.13128/IJAE-13904



Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License (CC-BY- 4.0)

 
Firenze University Press
Via Cittadella, 7 - 50144 Firenze
Tel. (0039) 055 2757700 Fax (0039) 055 2757712
E-mail: info@fupress.com